In the Original Investigation titled, “Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Randomized Clinical Trial,”1 published August 22, 2025, there was an error in the color of the bars in the bottom panel of Figure 1B. The bars at the right with a neoadjuvant score above 16 were changed from green to red, indicating a high score. This article has been corrected.1
Reference
- 1.Laengle J, Kuehrer I, Kulu A, et al. Dual immune checkpoint inhibition plus neoadjuvant chemoradiotherapy in rectal cancer: a randomized clinical trial. JAMA Netw Open. 2025;8(8):e2527769. doi: 10.1001/jamanetworkopen.2025.27769 [DOI] [PMC free article] [PubMed] [Google Scholar]
